Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery

American Journal of Surgical Pathology

Volumn 38, Issue 6, 2014, Pages 729-742

  Rabban, Joseph T ^a   Garg, Karuna ^a   Crawford, Beth ^a   Chen, Lee May ^b   Zaloudek, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRCA; Cancer detection; Fallopian tubes; Pelvic high grade serous carcinoma; Tubal carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; KI 67 ANTIGEN; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOMA IN SITU; CELL PROLIFERATION; CHEMISTRY; EARLY DIAGNOSIS; FEMALE; GENETICS; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; MIDDLE AGED; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; SALPINGECTOMY; UTERINE TUBE; UTERINE TUBE TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA IN SITU; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDINGS; KI-67 ANTIGEN; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SALPINGECTOMY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84900806761     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000199     Document Type: Article

References (60)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29
2. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107:159-162
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: Breast and ovarian. Version 2. National Comprehensive Cancer Network; 2013. Available at: Http://www.nccn.org. Accessed November 2013
4. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654-2663
5. Berchuck A, Heron KA, Carney ME, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res. 1998;4:2433-2437
6. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807-2816
7. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710
8. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694-1706
9. Rodriguez AO, Llacuachaqui M, Pardo GG, et al. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol. 2012;124:236-243
10. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997;336:1125-1130
11. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353-357
12. United States Preventive Services Task Force. Screening for ovarian cancer. Available at: Http://www.uspreventiveservicestaskforce.org/ uspstf/uspsovar.htm. Accessed November, 2013
13. Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: Etiology, screening and surveillance. Gynecol Oncol. 2010;119:7-17
14. American Cancer Society. Ovarian cancer. Can ovarian cancer be found early?. Available at: Http://www.cancer.org/cancer/ovariancancer/ detailedguide/ovarian-cancer-detection. Accessed November 2013
15. Crum CP, McKeon FD, Xian W. BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer. 2012;22(suppl 1):S29-S34
16. Kurman RJ, Shih I. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42:918-931
17. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: Report of 6 cases and review of the literature. Am J Surg Pathol. 2006;30:1222-1230
18. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: Prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25: 1283-1289
19. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64
20. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236
21. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingooophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127-132
22. Rabban JT, Mackey A, Powell CB, et al. Correlation of macroscopic and microscopic pathology in risk reducing salpingooophorectomy: Implications for intraoperative specimen evaluation. Gynecol Oncol. 2011;121:466-471
23. Anderson CK, Wallace S, Guiahi M, et al. Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer. 2013;23:417-421
24. Chene G, Rahimi K, Mes-Masson AM, et al. Surgical implications of the potential new tubal pathway for ovarian carcinogenesis. J Minim Invasive Gynecol. 2013;20:153-159
25. Dietl J, Wischhusen J, Hausler SF. The post-reproductive Fallopian tube: Better removed?. Hum Reprod. 2011;26:2918-2924
26. Dietl J, Wischhusen J. The forgotten fallopian tube. Nat Rev Cancer. 2011;11:227
27. Dwyer PL. Ovarian cancer and the pelvic floor surgeon: The case for prophylactic bilateral salpingectomy during POP surgery. Int Urogynecol J. 2012;23:655-656
28. Erickson BK, Conner MG, Landen CN Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013;209:409-414
29. Gilks CB, Miller D. Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: The time has come. Gynecol Oncol. 2013;129:443-444
30. Morelli M, Venturella R, Mocciaro R, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere. Gynecol Oncol. 2013;129:448-451
31. Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol. 2012;10:296-306
32. Jacoby VL, Autry A, Jacobson G, et al. Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. Obstet Gynecol. 2009;114:1041-1048
33. Chan LM, Westhoff CL. Tubal sterilization trends in the United States. Fertil Steril. 2010;94:1-6
34. Whiteman MK, Hillis SD, Jamieson DJ, et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol. 2008;198:34-37
35. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingooophorectomies from women with BRCA mutations: Implications for defining an optimal specimen Dissection protocol. Am J Surg Pathol. 2009;33:1878-1885
36. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: A descriptive classification. Int J Gynecol Pathol. 2008;27:1-9
37. Mehrad M, Ning G, Chen EY, et al A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol. 2010;17:293-302
38. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012;31:243-253
39. Crum CP, Amarosa EJ. The fallopian tube and broad ligament. In: Crum CP, Nucci M, Lee KR, eds. Diagnostic Gynecologic and Obstetric Pathology. Philadelphia: Saunders; 2011;646
40. Longacre TA, Oliva E, Soslow RA. Recommendations for the reporting of fallopian tube neoplasms. Hum Pathol. 2007;38:1160-1163
41. Lester S. Manual of Surgical Pathology. Philadelphia: Saunders; 2010
42. Robboy SJ, Mutter GL, Shako-Levy R, et al. Cutup - gross description and processing ofspecimens. In: Robboy SJ, Mutter GL, Prat J, et al, eds. Robboy's Pathology of the Female Reproductive Tract. Churchill Livingstone; 2009;991
43. Hunt JL, Lynn AA. Histologic features of surgically removed fallopian tubes. Arch Pathol Lab Med. 2002;126:951-955
44. Yanai-Inbar I, Silverberg SG. Mucosal epithelial proliferation of the fallopian tube: Prevalence, clinical associations, and optimal strategy for histopathologic assessment. Int J Gynecol Pathol. 2000;19: 139-144
45. Semmel DR, Folkins AK, Hirsch MS, et al. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol. 2009;22:985-988
46. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009;22:1133-1138
47. Carcangiu ML, Radice P, Manoukian S, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004;23:35-40
48. Mingels MJ, Roelofsen T, van Der Laak JA, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol. 2012;127:88-93
49. Tang S, Onuma K, Deb P, et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: A study of 300 consecutive cases. Int J Gynecol Pathol. 2012;31:103-110
50. Visvanathan K, Vang R, Shaw P, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: A reproducibility study. Am J Surg Pathol. 2011;35:1766-1775
51. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingooophorectomy (RRSO) in BRCA mutation carriers: Experience with a consecutive series of 111 patients using a standardized surgicalpathological protocol. Int J Gynecol Cancer. 2011;21:846-851
52. Manchanda R, Abdelraheim A, Johnson M, et al. Outcome of riskreducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG. 2011;118:814-824
53. Powell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol. 2013;129:364-371
54. Gross AL, Kurman RJ, Vang R, et al. Precursor lesions of highgrade serous ovarian carcinoma: Morphological and molecular characteristics. J Oncol. 2010;2010:126295
55. Leonhardt K, Einenkel J, Sohr S, et al. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol. 2011;30:417-424
56. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-Associated fallopian tube carcinoma: A distinct clinical phenotype?. Obstet Gynecol. 2005;106:1327-1334
57. Colgan TJ. Challenges in the early diagnosis and staging of Fallopian-Tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol. 2003;22:109-120
58. Leunen K, Legius E, Moerman P, et al. Prophylactic salpingooophorectomy in 51 women with familial breast-ovarian cancer: Importance of fallopian tube dysplasia. Int J Gynecol Cancer. 2006; 16:183-188
59. Piek JM, Van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456
60. Clarke BA, Crum CP, Nucci MR, et al. College of American Pathologists: Protocol for the examination of specimens from patients with carcinoma of the fallopian tube. Available at: Http:// www.cap.org. Accessed November, 2013.